Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
$55.13
+8.7%		$65.28
$47.23
▼
$123.75
$536.42M-5.22206,973 shs47,857 shs
Evolus, Inc. stock logo
EOLS
Evolus
$7.62
+5.5%		$8.16
$3.86
▼
$9.31
$504.62M1.33998,896 shs235,354 shs
Oculis Holding AG stock logo
OCS
Oculis
$7.53
+5.0%		$10.96
$7.11
▼
$34.47
$436.30M0.62425,416 shs136,531 shs
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
$35.35
+17.6%		$33.21
$8.94
▼
$73.00
$124.19M1.2955,876 shs8,730 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-1.27%-2.48%-19.99%-31.69%-25.83%
Evolus, Inc. stock logo
EOLS
Evolus
-3.86%-6.72%-8.95%+28.24%+13.34%
Oculis Holding AG stock logo
OCS
Oculis
-5.91%-15.65%-32.36%-43.14%-66.71%
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
-23.61%-19.11%+2.88%+171.21%+180.84%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
$55.13
+8.7%		$65.28
$47.23
▼
$123.75
$536.42M-5.22206,973 shs47,857 shs
Evolus, Inc. stock logo
EOLS
Evolus
$7.62
+5.5%		$8.16
$3.86
▼
$9.31
$504.62M1.33998,896 shs235,354 shs
Oculis Holding AG stock logo
OCS
Oculis
$7.53
+5.0%		$10.96
$7.11
▼
$34.47
$436.30M0.62425,416 shs136,531 shs
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
$35.35
+17.6%		$33.21
$8.94
▼
$73.00
$124.19M1.2955,876 shs8,730 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-1.27%-2.48%-19.99%-31.69%-25.83%
Evolus, Inc. stock logo
EOLS
Evolus
-3.86%-6.72%-8.95%+28.24%+13.34%
Oculis Holding AG stock logo
OCS
Oculis
-5.91%-15.65%-32.36%-43.14%-66.71%
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
-23.61%-19.11%+2.88%+171.21%+180.84%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
2.91
Moderate Buy$144.71162.50% Upside
Evolus, Inc. stock logo
EOLS
Evolus
2.50
Moderate Buy$14.5090.41% Upside
Oculis Holding AG stock logo
OCS
Oculis
2.80
Moderate Buy$39.44424.18% Upside
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest RFAI, EOLS, DRUG, and OCS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$150.00
10/8/2026
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (D+) ➝ Hold (C-)
9/28/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Lifesci Capital logo
Lifesci Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong-Buy
9/18/2026
Oculis Holding AG stock logo
OCS
Oculis
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$26.00 ➝ $39.00
9/15/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeStrong-Buy ➝ Hold
9/11/2026
Evolus, Inc. stock logo
EOLS
Evolus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/4/2026
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (D) ➝ Sell (D+)
8/25/2026
Oculis Holding AG stock logo
OCS
Oculis
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
8/25/2026
Evolus, Inc. stock logo
EOLS
Evolus
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$13.00
8/21/2026
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold (C-) ➝ Sell (D)
8/20/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeMarket Perform
(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/AN/AN/AN/A$8.33 per shareN/A
Evolus, Inc. stock logo
EOLS
Evolus
$316.49M1.59N/AN/A($0.36) per share-21.15
Oculis Holding AG stock logo
OCS
Oculis
$1.45M300.90N/AN/A$4.08 per share1.84
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-$8.74M-$2.08N/AN/AN/AN/A-12.46%-12.30%12/22/2026 (Estimated)
Evolus, Inc. stock logo
EOLS
Evolus
-$51.64M-$0.52N/A84.61N/A-10.85%N/A-13.00%11/4/2026 (Estimated)
Oculis Holding AG stock logo
OCS
Oculis
-$119.44M-$1.74N/AN/AN/A-6,777.18%-42.61%-35.23%11/5/2026 (Estimated)
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest RFAI, EOLS, DRUG, and OCS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Oculis Holding AG stock logo
OCS
Oculis
-$0.49N/AN/AN/A$0.25 millionN/A
11/4/2026Q3 2026
Evolus, Inc. stock logo
EOLS
Evolus
-$0.05N/AN/AN/A$77.58 millionN/A
8/14/2026Q3 2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-$1.2230-$0.17+$1.0530-$0.17N/AN/A
8/7/2026Q2 2026
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
N/A$0.01N/A$0.01N/AN/A
8/6/2026Q2 2026
Oculis Holding AG stock logo
OCS
Oculis
-$0.48-$0.20+$0.28-$0.20$0.22 million$0.38 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
Oculis Holding AG stock logo
OCS
Oculis
N/AN/AN/AN/AN/A
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/A
122.00
122.00
Evolus, Inc. stock logo
EOLS
Evolus
N/A
1.70
1.28
Oculis Holding AG stock logo
OCS
Oculis
0.01
8.35
8.35
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
40.52%
Evolus, Inc. stock logo
EOLS
Evolus
90.69%
Oculis Holding AG stock logo
OCS
Oculis
22.30%
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
N/A

Insider Ownership

CompanyInsider Ownership
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
42.66%
Evolus, Inc. stock logo
EOLS
Evolus
5.00%
Oculis Holding AG stock logo
OCS
Oculis
N/A
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
39.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
259.73 million5.58 millionNot Optionable
Evolus, Inc. stock logo
EOLS
Evolus
35366.05 million62.75 millionOptionable
Oculis Holding AG stock logo
OCS
Oculis
6057.98 millionN/ANot Optionable
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
23.51 million2.14 millionN/A

Recent News About These Companies

RF Acquisition Corp II (NASDAQ:RFAI) Stock Moved Up to Sell by Wall Street Zen
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104243
Aktien»Nachrichten»STABLECOINX AKTIE»Morning Market Movers: RF Acquisition Corp II, SU Group, T3 Defense, StablecoinX See Big Swings
October 8, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69375394-morning-market-movers-rf-acquisition-corp-ii-su-group-t3-defense-stablecoinx-see-big-swings-020.htm
RF Acquisition Corp II (NASDAQ:RFAI) Short Interest Update
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-rf-acquisition-corp-ii-nasdaq-rfai-short-interest-update-2026-10-01/
Cours RF Acquisition Corp II
September 26, 2026  |  zonebourse.comZ
The9 Reports US$32 Million Net Income for Second Quarter of 2026, Up Over 39% Sequentially
August 24, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/the9-reports-us32-million-net-income-for-second-quarter-of-2026-up-over-39-sequentially-302858240.html
RF Acquisition Corp II Ordinary Shares
August 21, 2026  |  livemint.comhttps://www.livemint.com/market/market-stats/us-stocks-rf-acquisition-corp-ii-share-price-rfai
RF Acquisition Corp. Stock Skyrockets Following Key SEC Filings
August 21, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/08/61353509/rf-acquisition-corp-stock-skyrockets-following-key-sec-filings
RF Acquisition Corp II Shareholders Approve Merger Plans
August 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/rf-acquisition-corp-ii-shareholders-approve-merger-plans?utm_source=marketbeat.com&utm_medium=referral
RF Acquisition Corp II Shareholders Approve Extension Amendments
August 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/rf-acquisition-corp-ii-shareholders-approve-extension-amendments?utm_source=marketbeat.com&utm_medium=referral
RF Acquisition Corp II (RFAI) Holds Steady Near Support as SPAC Trading Remains Tepid - Day Trade Opportunities
July 14, 2026  |  donanimhaber.comD
HCC Healthcare Signs Business Combination Agreement with RF Acquisition Corp III to Go Public on Nasdaq
July 9, 2026  |  quiverquant.comQ
Rf Acquisition Corp II
June 29, 2026  |  fool.comhttps://www.fool.com/quote/nasdaq/rfai/
RF Acquisition Corp. II Rt
April 15, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/rfair
RF Acquisition Corp. II
April 8, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/rfai
RF Acquisition Corp III Completes Initial Public Offering of 10 Million Units on Nasdaq
February 18, 2026  |  quiverquant.comQ
RF Acquisition Corp III Prices Initial Public Offering of 10 Million Units at $10.00 Each on Nasdaq
February 12, 2026  |  quiverquant.comQ
RF Acquisition Corp II Announces Merger with Nanyang Biologics
October 2, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/rf-acquisition-corp-ii-announces-merger-with-nanyang-biologics?utm_source=marketbeat.com&utm_medium=referral
RF Acquisition Corp II Audit Committee Resignation
May 21, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/rf-acquisition-corp-ii-audit-committee-resignation?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Viking Therapeutics logo displayed among laboratory glassware, a vial, and a syringe in a lab setting.
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
By Chris Markoch | September 23, 2026
Three-panel composite showing a laboratory workbench, an open-plan office with desks, and a pharmacy with stocked medicine shelves.
3 Healthcare Stocks for 3 Stages of Life
By Jessica Mitacek | September 15, 2026
Novo Nordisk logo displayed in a laboratory setting with vials, an insulin pen, and a researcher in the background.
Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?
By Thomas Hughes | September 23, 2026
Three-panel image showing an office call center, a man doing resistance-band exercise via video telehealth session, and lab technicians analyzing medical scans.
3 Healthcare Stocks Showing Why the Sector Still Has Momentum
By Nathan Reiff | September 28, 2026
Lab vials with colored liquids on a counter while a researcher reviews data near screens showing anatomical and virus imagery.
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
By Jessica Mitacek | October 10, 2026
Bright Minds Biosciences stock logo

Bright Minds Biosciences NASDAQ:DRUG

$55.13 +4.42 (+8.72%)
As of 12:07 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Evolus stock logo

Evolus NASDAQ:EOLS

$7.62 +0.40 (+5.47%)
As of 12:08 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Oculis stock logo

Oculis NASDAQ:OCS

$7.52 +0.36 (+4.95%)
As of 12:08 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

RF Acquisition Corp II stock logo

RF Acquisition Corp II NASDAQ:RFAI

$35.35 +5.30 (+17.64%)
As of 12:07 PM Eastern
This is a fair market value price provided by Massive. Learn more.

RF Acquisition Corp. II operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 5, 2024, and is headquartered in Singapore.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas